{
    "clinical_study": {
        "@rank": "166371", 
        "arm_group": [
            {
                "arm_group_label": "Treatment Group", 
                "description": "This group consists of patients diagnosed with homocysteinemia who have been treated with Cerefolin\u00ae/CerefolinNAC\u00ae in the past or are currently being treated with Cerefolin\u00ae/CerefolinNAC\u00ae."
            }, 
            {
                "arm_group_label": "Non-Treatment Group", 
                "description": "This group consists of patients not diagnosed with homocysteinemia who have no past or current treatment with Vitamin B12, Folate or Cerefolin\u00ae/CerefolinNAC\u00ae."
            }
        ], 
        "biospec_descr": {
            "textblock": "A single blood draw for approximately 6-10 mL of blood will be performed for the total\n      plasma homocysteine measurement and genetic studies."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "In a retrospective analysis of data from 1100 patients, disease-delaying effects of\n      Cerefolin\u00ae/CerefolinNAC\u00ae were examined in terms of cognition.  The purpose of the current\n      study is to expand the retrospective study dataset by prospectively collecting additional\n      biomarker and imaging data."
        }, 
        "brief_title": "Effect of Cerefolin\u00ae/CerefolinNAC\u00ae on Biomarker Measurements", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Mild Cognitive Impairment", 
            "Alzheimer's Disease", 
            "Alzheimer's Disease Related Disorders"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alzheimer Disease", 
                "Cognition Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "CerefolinNAC\u00ae is an orally administered prescription medical food, and is formulated as a\n      combination of L-methylfolate calcium (as Metafolin\u00ae), methylcobalamin, and\n      N-acetylcysteine. In a retrospective analysis, disease-delaying effects of\n      Cerefolin\u00ae/CerefolinNAC\u00ae (CFLN) are examined in terms of cognition (measured by MCI Screen\n      (MCIS)), and functional capacity (measured by Functional Assessment Staging Test (FAST)).  -\n      the treatment effect of CFLN on cognitive and functional measures, and on biomarker measures\n      in patients with Alzheimer's disease and related disorders (ADRD).\n\n      The current study will expand the NAC-002b study dataset by prospectively collecting\n      additional biomarker and imaging data in a more comprehensively assessed, matched sample of\n      patients. This will allow more precise evaluation of cognitive and functional outcome\n      measures, and biomarker measures will be assessed in an attempt to identify specific\n      populations or conditions in which CFLN is most effective.\n\n      The sample will consist of patients with homocysteinemia plus past/current CFLN treatment\n      (Treatment Group) matched to those without homocysteinemia plus no past/current B12, folate\n      or CFLN treatment (Non-Treatment Group). Also 65 additional subjects will be recruited for\n      the non-Treatment group, which will be used to improve the rate of decline estimates for the\n      cognitive and functional outcome measures."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  With a diagnosis of normal aging (NL), cognitive impairment or dementia not otherwise\n             specified (CI/D), or ADRD\n\n          -  With at least one previous quantitative MRI (qMRI)\n\n          -  With at least one previous homocysteine level\n\n          -  Without homocysteinemia plus no past or current B12, folate or Cerefolin\u00ae treatment,\n             OR with homocysteinemia plus past or current Cerefolin\u00ae treatment\n\n        Exclusion Criteria:\n\n        Subjects who do not meet the inclusion criteria will be excluded from the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with homocysteinemia plus past/current CFLN treatment (Treatment Group) will be\n        matched to those without homocysteinemia plus no past/current B12, folate or CFLN\n        treatment (Non-Treatment Group)."
            }
        }, 
        "enrollment": {
            "#text": "119", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01745198", 
            "org_study_id": "NAC-002c"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "homocysteinemia", 
            "dementia", 
            "depression", 
            "vitamin B12", 
            "folate", 
            "mild cognitive impairment", 
            "alzheimer's", 
            "homocysteine"
        ], 
        "lastchanged_date": "December 19, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Newport Beach", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92663"
                }, 
                "name": "Hoag Memorial Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Effect of Cerefolin\u00ae/CerefolinNAC\u00ae on Biomarker Measurements in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Related Disorders", 
        "overall_official": {
            "affiliation": "Shankle Clinic", 
            "last_name": "William R Shankle, MS, MD, FACP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in MPI over time will be calculated using multiple retrospective time points.", 
            "measure": "Change in rate of cognitive decline as measured by the Memory Performance Index (MPI)", 
            "safety_issue": "No", 
            "time_frame": "Baseline to end of study (estimated average of 48 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01745198"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in MCI Screen over time will be calculated using multiple retrospective time points.", 
                "measure": "Change in rate of cognitive decline as measured by the MCI Screen", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of study (estimated average of 48 months)"
            }, 
            {
                "description": "Change in CERAD drawings over time will be evaluated using multiple retrospective time points", 
                "measure": "Change in rate of cognitive decline as measured by The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Drawings", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of study (estimated average of 48 months)"
            }, 
            {
                "description": "Change in Trails A & B over time will be assessed using multiple retrospective time points", 
                "measure": "Change in rate of cognitive decline as measured by Trails A & B", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of study (estimated average of 48 months)"
            }, 
            {
                "description": "Decrease in hippocampal volume over time will be assessed using volumetric MRI", 
                "measure": "Rate of atrophy of hippocampal volume", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of study (estimated average of 48 months)"
            }, 
            {
                "description": "Decrease in cortical volume over time will be assessed using volumetric MRI", 
                "measure": "Rate of atrophy in cortical volume", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of study (estimated average of 48 months)"
            }, 
            {
                "description": "Decrease in ventricular volume over time will be assessed using volumetric MRI", 
                "measure": "Rate of atrophy in ventricular volume", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of study (estimated average of 48 months)"
            }, 
            {
                "description": "Change in FAST  over time will be calculated using multiple retrospective time points.", 
                "measure": "Change in rate of cognitive decline as measured by Functional Assessment Staging Test (FAST)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to end of study (estimated average of 48 months)"
            }
        ], 
        "source": "Pamlab, Inc.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "The Shankle Clinic", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hoag Memorial Hospital Presbyterian", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Pamlab, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}